Literature DB >> 2236008

Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

T Waddell1, A Cohen, C A Lingwood.   

Abstract

Verotoxin 1 is an Escherichia coli-derived subunit toxin that specifically binds to the glycolipid globotriosylceramide and is cytotoxic for cells that contain this plasma membrane glycolipid. Glycolipid incorporation experiments have now been performed using human lymphoid cells of the B lineage that lack this receptor, to conclusively demonstrate that globotriosylceramide alone is a functional receptor for this toxin. Globotriosylceramide incorporated into the membrane of toxin-resistant cells provides intracellular access to verotoxin by receptor-mediated endocytosis. Protein synthesis is then inhibited and globotriosylceramide-containing cells are killed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2236008      PMCID: PMC54858          DOI: 10.1073/pnas.87.20.7898

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor.

Authors:  A Cohen; G E Hannigan; B R Williams; C A Lingwood
Journal:  J Biol Chem       Date:  1987-12-15       Impact factor: 5.157

2.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

3.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.

Authors:  N A Strockbine; L R Marques; J W Newland; H W Smith; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

4.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

Review 5.  Unravelling HUS.

Authors: 
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

6.  Pathogenesis of haemolytic uraemic syndrome.

Authors:  T G Obrig; P J Del Vecchio; M A Karmali; M Petric; T P Moran; T K Judge
Journal:  Lancet       Date:  1987-09-19       Impact factor: 79.321

7.  Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1.

Authors:  A A Lindberg; J E Brown; N Strömberg; M Westling-Ryd; J E Schultz; K A Karlsson
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

Review 8.  Sulfatide-binding proteins.

Authors:  D D Roberts
Journal:  Chem Phys Lipids       Date:  1986-12-15       Impact factor: 3.329

9.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

10.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  40 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

Review 2.  A Toxic Environment: a Growing Understanding of How Microbial Communities Affect Escherichia coli O157:H7 Shiga Toxin Expression.

Authors:  Erin M Nawrocki; Hillary M Mosso; Edward G Dudley
Journal:  Appl Environ Microbiol       Date:  2020-11-24       Impact factor: 4.792

Review 3.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

4.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

Review 5.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

6.  Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Authors:  Abhineet S Sheoran; Susan Chapman-Bonofiglio; Barrett R Harvey; Jean Mukherjee; George Georgiou; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Interaction of the verotoxin 1B subunit with soluble aminodeoxy analogues of globotriaosyl ceramides.

Authors:  Murugesapillai Mylvaganam; Henrik C Hansen; Beth Binnington; Göran Magnusson; Per-Georg Nyholm; Clifford A Lingwood
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

8.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Verotoxin induces hemorrhagic lesions in rat small intestine. Temporal alteration of vasoactive substances.

Authors:  H Tashiro; S Miura; I Kurose; D Fukumura; H Suzuki; M Suematsu; M Yoshioka; M Tsuchiya; A Kai; Y Kudoh
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

10.  Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells. Verotoxin binding studies.

Authors:  J Pereira; B Boyd; J Newbigging; C Lingwood; P M Strasberg
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.